VR Logo

Amicus Therapeutics Inc. (FOLD) download report


Healthcare | Biotechnology & Pharma Research

Amicus Therapeutics Inc. (FOLD) Premium Coverage

52 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases.

IPO Date: 31-May-2007

Chairman & CEO: Mr. John F. Crowley

Pres, COO & Director: Mr. Bradley L. Campbell M.B.A.

Listing: NASDAQ: FOLD

Country: United States

Headquarters: Philadelphia, PA

Website: https://amicusrx.com

Key Facts

Market cap: $3,115.41 Mln

Revenue (TTM): $317.83 Mln

Earnings (TTM): $-270.06 Mln

Cash: $411.20 Mln

Total Debt: $447.71 Mln

Insider's Holding: 1.07%

Liquidity: Low

52 Week range: $5.91 - 12.63

Shares outstanding: 280,163,008

10 Years Aggregate:

  • CFO: $-1,583.52 Mln
  • EBITDA: $-2,026.86 Mln
  • Net Profit: $-2,026.20 Mln

Stock Performance

Time Period Amicus Therapeutics (FOLD) S&P BSE Sensex S&P Small-Cap 600
YTD-8.66-8.71-17.92
1 month32.70-3.11-7.88
3 months12.96-7.30-13.56
1 Year1.640.48-17.16
3 Years-4.2010.346.95
5 Years1.6511.436.30
10 Years6.3512.1010.29
As on 28-Jun-2022
Year Amicus Therapeutics (FOLD) S&P Small-Cap 600 S&P BSE Sensex
2021-49.9825.2721.99
2020137.069.5715.75
20191.6720.8614.38
2018-33.28-9.705.87
2017189.5411.7327.91
2016-48.7624.741.95
201516.59-3.36-5.03